Lead Product(s) : RX-5902
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Rexahn Pharmaceuticals Inc
Deal Size : Undisclosed
Deal Type : Termination
Rexahn Pharmaceuticals Terminates Breast Cancer Study with Merck
Details : The company had previously disclosed that it was evaluating the development strategy for RX-5902, including whether to proceed with the trial.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
April 09, 2020
Lead Product(s) : RX-5902
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Rexahn Pharmaceuticals Inc
Deal Size : Undisclosed
Deal Type : Termination
LOOKING FOR A SUPPLIER?